Company intelligence / Profile preview

Tburd

Ownership: Private
Development stage: Other

Overview

Third Harmonic Bio’s lead program, THB335—a small molecule KIT inhibitor—demonstrated dose-dependent reductions in serum tryptase in healthy volunteers during a Phase 1 trial. The company abandoned plans for a Phase 2 study in chronic spontaneous urticaria and is now liquidating its business while seeking buyers for its clinical assets.

Therapeutic areas: Immunology
Modalities: Small molecule
Industry: Biotech

Partnerships

TD Cowen was engaged for strategic alternatives during wind-down phase.

Beyond the preview

Go deeper on Tburd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tburd.

Explore the full profile